Natural Products Insider

SEP-OCT 2017

INSIDER is the leading information source for marketers, manufacturers and formulators of dietary supplements, healthy foods and cosmeceuticals. Since 1997, INSIDER has been serving the needs of the global nutrition industry.

Issue link:

Contents of this Issue


Page 24 of 160

18 INSIDER September/October 2017 indicative of liver damage when at high levels—were reduced by the end of trial in the curcumin group, but elevated in the placebo group. Additionally, curcumin's ability to reduce serum AST and ALT levels was also signifi cant in the between-group comparison. Ultrasonographic fi ndings improved in 75 percent of subjects in the curcumin group, while the rate of improvement in the control group was 4.7 percent. Additional research published in 2017 indicated curcumin may be effective in treating NAFLD per its ability to activate adenosine monophosphate (AMP)- activated protein kinase (AMPK), the main cellular energy sensor, which has been implicated as a key regulator of hepatic lipid and glucose metabolism. 14 New research conducted in mice determined curcumin's ability to suppress ethanol-induced pathways—including biosynthesis of unsaturated fatty acids, fatty acid biosynthesis, and pentose and glucuronate interconversions, indicating a positive effect on alcoholic fatty liver. 15 NAFLD is often related to metabolic disorders such as dyslipidemia and type 2 diabetes. According to results of a randomized, double-blind, placebo-controlled trial, curcuminoid supplementation (1000 mg/d, as Curcumin C3 Complex) along with 10 mg/d black pepper extract (as BioPerine ® , from Sabinsa) in type 2 diabetic patients for three months resulted in signifi cant protection against oxidative stress. 16 This research suggests curcumin is a safe and effective antioxidant supplement in managing oxidative stress-mediated progression of type 2 diabetes and its long-term complications, commented Shaheen Majeed, president, Sabinsa Worldwide. In subjects with metabolic syndrome, eight weeks of supplementation with curcumin (500 mg as Curcumin C3 Complex) and BioPerine (5 mg) resulted in signifi cant reduction of serum concentrations of the infl ammatory signaling molecules tumor necrosis factor-alpha (TNF-α), IL-6, transforming growth factor beta (TGF-β) and monocyte chemoattractant protein-1 (MCP-1) (P<0.001). Researchers concluded, "Results of the present study suggest that curcumin supplementation signifi cantly decreases serum concentrations of pro-infl ammatory cytokines in subjects with [metabolic syndrome]." 17 In rats with a high-fructose diet (HFD)- induced metabolic syndrome, curcumin supplementation produced signifi cant improvements in all glucose and fat metabolism parameters (body mass, systolic blood pressure, homeostasis model assessment Supplements: Curcumin

Articles in this issue

Archives of this issue

view archives of Natural Products Insider - SEP-OCT 2017